Compare BP prices and BP side effects to medical cannabis

New Post Public Reply Private Reply Replies (0) Message Board
bellsandwhistles
Compare BP prices and BP side effects to medical cannabis for pain relief. Deaths from prescription drugs now exceed all deaths from the most dangerous illegal drugs. No deaths have been directly attributed to cannabis overdose (smoking 1500 lbs. at one sitting is thought to be lethal dose). From several sources.

Prescription drug abuse is now more deadly than heroin and cocaine combined, according to a recent article in the CS Monitor. Where's the official outrage against Big Pharma? Looking at the prices of "legal" pharmaceuticals, one can figure out why they're silent.

http://www.csmonitor.com/USA/Society/2013/100...e-combined
October 7, 2013
"More people are dying in the United States from prescription drugs than from heroin and cocaine combined, a new study says, signaling that pill abuse is not just the leading cause of drug overdose deaths, but that it also requires more oversight and training by both doctors and state health agencies. "

===================

Dollar costs
ZOLOFT: 30 days: 146.00
VICODIN: 30 days: 200.00
AMBIEN: 30 days: 176.00

SAMHSA noted 74% of all emergency department visits involving adverse reactions to Ambien were made by people aged at least 45 years. According to public records,4,916,328 Americans made drug-related visits to emergency departments (2010). In 2007, pain medication Fentanyl killed more than 1,000 people in the US.

Every day in the US, 2,500 youth (12 to 17) abuse a prescription pain reliever for the first time.

Prescription drug abuse, while most prevalent in the US, is a problem in many areas around the world including Europe, Southern Africa and South Asia. In the US alone, more than 15 million people abuse prescription drugs, more than the combined number who reported abusing cocaine, hallucinogens, inhalants and heroin.

In 2006 in the United States, 2.6 million people abused prescription drugs for the first time.

A 2007 survey in the US found that 3.3% of 12- to 17-year-olds and 6% of 17- to 25-year-olds had abused prescription drugs in the past month.

Prescription drug abuse causes the largest percentage of deaths from drug overdosing. Of the 22,400 drug overdose deaths in the US in 2005, opioid painkillers were the most commonly found drug, accounting for 38.2% of these deaths.

In 2005, 4.4 million teenagers (aged 12 to 17) in the US admitted to taking prescription painkillers, and 2.3 million took a prescription stimulant such as Ritalin. 2.2 million abused over-the-counter drugs such as cough syrup. The average age for first-time users is now 13 to 14.

CAUSE OF DEATHS
Prescription Drugs: 45%
Street Drugs Combined: 39%

Depressants, opioids and antidepressants are responsible for more overdose deaths (45%) than cocaine, heroin, methamphetamine and amphetamines (39%) combined. In the United States, the most deaths used to take place in inner cities in African-American neighborhoods, but they have now been overtaken by white rural communities. The same trend can be seen in the rates of hospitalization for substance abuse and emergency hospitalization for overdoses. Of the 1.4 million drug-related emergency room admissions in 2005, 598,542 were associated with abuse of pharmaceuticals alone or with other drugs.

By survey, almost 50% of teens believe that prescription drugs are much safer than illegal street drugs— 60% to 70% say that home medicine cabinets are their source of drugs.

According to the National Center on Addiction and Substance Abuse at Columbia University, teens who abuse prescription drugs are twice as likely to use alcohol, five times more likely to use marijuana, and twelve to twenty times more likely to use illegal street drugs such as heroin, Ecstasy and cocaine than teens who do not abuse prescription drugs.


MJ even less addictive than caffeine.



SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Updated Category News Views 24

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...

Continue Reading
Samuel Oschin Air & Space Center Takes Flight This Fall

Updated Category News Views 98

The Grand Unveiling: November Highlights Look at this: space nerds, dreamers, and just about anybody with a heartbeat and a sense of wonder should circle November 13, 2026, like a kid with a candy store gift card. That's when the California Science Center throws open the doors to the Samuel Oschin Air and Space Center. You might as well slap a 'world's first' sticker on...

Continue Reading
Unicycive Faces Legal Heat: Shareholder Lawsuit Looms

Updated Category News Views 104

The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...

Continue Reading
Navigating Gas-to-AI Power: Challenges & Opportunities

Updated Category News Views 83

Natural Gas Abundance Meets Conversion Hurdles It’s a wild scene when you've got oodles of natural gas but struggle to get it into AI data centers. That’s the picture today: U.S. gas production hitting a high of 137 billion cubic feet daily, while converting that gas into practical energy is the real challenge. You see, the gas market is ready to rumble, ticking...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Replay Sports Cards Nets STAR Award for Innovation

Updated Category News Views 82

A New Era for Franchise Onboarding Just when you think the sports card world couldn't get any more niche, along comes Replay Sports Cards thumping its chest with some serious innovation. This Charlotte-based franchise just snagged the Franchise Innovation Award from Franchise Update Media. Yep, they're the only ones getting tips of the hat for the Most Innovative...

Continue Reading
Step into Fear: Dead by Daylight in Moreno Valley

Updated Category News Views 54

Immersive Horror in Moreno Valley Walking straight into the fog of your nightmares isn't for the faint-hearted, but that's the kind of thrill the Moreno Valley Museum & ArtSpace is serving up with its new Dead by Daylight Immersive Experience. Kicking off just in time for Halloween on October 30, this isn't your average stroll in a museum—it's a heart-pounding,...

Continue Reading
Armani/Casa Miami Earns Forbes Designation for Luxury

Updated Category News Views 34

Where Luxury Meets Thoughtfulness Residences by Armani/Casa Miami just nabbed a VERIFIED™ Luxury Residences badge from the Forbes Travel Guide folks. Now, you might be wondering why this is significant or if it's just another shiny tag in a world already glistening with luxury concepts. Well, there's a shift happening here, and it's got some meat to it. The folks...

Continue Reading
South Dakota's BEES Launch: Child Care Assistance Goes Live

Updated Category News Views 24

RedMane and South Dakota DSS: A New Milestone Talk about a leap into the digital age. South Dakota's Department of Social Services, teaming up with RedMane Technology, has just rolled out the Child Care Assistance Program on their BEES platform. That’s Benefits Eligibility and Enrollment System for those not keeping track. It represents a significant step in making life...

Continue Reading
QFIN Faces Lawsuit Over Broken Promises and Revenue Plunge

Updated Category News Views 48

Unmasking the Hype: QFIN's Pledge and Performance Investors, gather 'round because QFIN's latest uproar ain't pretty. The folks over at Qfin Holdings have found themselves in hot water, facing a class action lawsuit for allegedly pulling the wool over investors' eyes. Between March and August 2026, they promised a rock-solid ship braving China’s regulatory storm. Turns...

Continue Reading

Top 5 Most Recently Viewed Articles

BCMGlobal Takes Charge of NFSC's Loan Servicing Evolution

Updated Category News Views 197

BCMGlobal's New Role in Advancing NFSC BCMGlobal has been appointed to strategically manage the National Financing Support Services Company (NFSC), elevating it to a leading independent loan servicer. This initiative aims to promote excellence in the sector. Supporting Saudi Arabia's Financial Vision The NFSC, established with the backing of the Saudi Real Estate...

Continue Reading
Breakthrough MRD Data from Myriad Genetics at Cancer Conference

Updated Category News Views 201

Innovative Insights into MRD Testing Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent name in molecular diagnostics and precision medicine, is set to unveil exciting new clinical findings related to their Precise MRD test at a significant annual meeting dedicated to cancer research. Presentation Highlights During the conference, Dr. Chad Tang from The University of Texas...

Continue Reading
SBM Offshore's Recent Share Buyback Program: Key Insights

Updated Category News Views 119

SBM Offshore's Share Buyback Program Overview SBM Offshore has recently reported on its significant share repurchase program, valued at EUR130 million (approximately US$140 million), covering transactions made from November 21, 2024, to November 27, 2024. This initiative underscores the company’s commitment to enhancing shareholder value through systematic buybacks. Key...

Continue Reading
Investigation into Akero Therapeutics by Berger Montague PC

Updated Category News Views 165

Akero Therapeutics Under Investigation by Berger Montague Berger Montague PC, a respected law firm, recently brought to attention an ongoing investigation into the practices of Akero Therapeutics, Inc. The investigation focuses on potential breaches of fiduciary duties and violations of federal securities laws by Akero’s Board of Directors, which has crucial...

Continue Reading
Nkarta's Upcoming Interactive Session: What to Expect?

Updated Category News Views 127

Nkarta to Engage with Investors in H.C. Wainwright Series Nkarta, Inc. (NASDAQ: NKTX), a pioneering clinical-stage biopharmaceutical firm dedicated to creating innovative engineered natural killer (NK) cell therapies, recently announced its notable role in the H.C. Wainwright "HCW@Home" Series. This virtual series will allow investors and interested parties to gain deeper...

Continue Reading